This study aims to evaluate the role of Montelukast in management of acute Bronchiolitis in indoor patient and how this drug shortens the duration of admission and improves symptoms
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
Administrating montelukast to experimental group and monitoring response
Placebo sugar granules administered orally once daily at night according to the same schedule as montelukast 4 mg sachet, in addition to standard supportive care for acute bronchiolitis
Pakistan Institute of Medical Sciences, Islamabad
Islamabad, Federal, Pakistan
RECRUITINGChange in Clinical Severity Score from Baseline to 72 Hours
Change in the study-defined Clinical Severity Score from baseline at hospital admission to 72 hours after initiation of treatment. The score ranges from 0 to 12 and is calculated from heart rate, wheezing, respiratory rate, dyspnea, respiratory support, and feeding difficulties, with each component scored from 0 to 2. Higher scores indicate greater clinical severity. The change in score will be compared between the montelukast and placebo groups
Time frame: Baseline (hospital admission) and 72 hours after initiation of treatment
Length of Hospital Stay
Length of hospital stay measured in hours from hospital admission until hospital discharge. Discharge is defined by resolution of symptoms, including improved feeding, absence of respiratory distress, a clinical severity score less than 3, and respiratory rate within the normal range for age.
Time frame: From baseline (hospital admission;day 1) through hospital discharge ( day 7)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.